Get the Daily Brief
Latest Biotech News
3D‑printed scaffolds boost glioblastoma drug screening
Researchers developed 3D‑printed scaffold models to better mimic glioblastoma microenvironments and improve preclinical drug screening fidelity. The scaffolds preserved tumor heterogeneity and...
Targeting FBXL5 reverses oxaliplatin resistance in colorectal cancer
A study by Wang et al. identified FBXL5 as a molecular driver of oxaliplatin resistance in iron‑rich colorectal cancers and showed that targeting FBXL5 sensitizes tumors to chemotherapy by...
Novartis to buy Avidity for $12B – Scores RNA neuromuscular pipeline
Novartis agreed to acquire Avidity Biosciences in a cash transaction that values the RNA-focused developer at about $12 billion. The deal, announced Sunday, buys Novartis three late-stage programs...
Nanopore cfDNA test spots tissue origin and pathogens in ICU patients
Researchers unveiled a nanopore sequencing workflow that analyzes plasma cell‑free DNA to report both tissue‑of‑origin signals and pathogen presence from a single blood draw. The approach was...
Metagenomic sequencing unmasks pneumonia pathogens at strain level
A team led by Zhou et al. published a strain‑level metagenomic sequencing study of pneumonia pathogens, demonstrating the ability to resolve intra‑species variation directly from clinical samples....
CAR‑based cell therapy expands into AML — CAR‑T and CAR‑NK advances
Researchers reviewed recent preclinical and early clinical work advancing CAR‑T and CAR‑NK approaches against acute myeloid leukemia (AML). The report synthesizes new antigen targets, engineering...
Nanotherapeutics program reprograms macrophages to tackle atherosclerosis
A preclinical study from Xu, Zhang and Yu outlines nanoparticle strategies designed to modulate macrophage behavior in atherosclerotic plaques. Investigators report targeted delivery systems that...
Long‑acting injectable buprenorphine reduces inpatient service use
A recent study reported that long‑acting injectable formulations of buprenorphine significantly lowered the need for inpatient care among patients with opioid use disorder. Researchers documented...
3D‑printed glioblastoma scaffolds and COX‑2 target reshape therapy testing
Two independent reports advance glioblastoma research from complementary angles: a 3D‑printed scaffold model that better replicates tumor microarchitecture for drug screening, and a separate study...
Mapping metabolic liver disease in India — new population signals
Two pieces examining metabolic dysfunction‑associated steatotic liver disease (MASLD) in Indian cohorts highlight rising prevalence and heterogeneous demographic risk. A letter and a mapping study...
Glycation accelerates alpha‑synuclein aggregation and neuroinflammation in Parkinson’s
Twin publications in npj Parkinson’s Disease report that protein glycation increases alpha‑synuclein aggregation and heightens neuroinflammatory responses in models relevant to Parkinson’s...
Wastewater rotavirus RNA reflects US infection and vaccination patterns
Researchers demonstrated that rotavirus RNA levels in wastewater correlate with regional infection prevalence and vaccination coverage across the United States. The study positions...
Biogen buys Vanqua C5aR1 program: $70M up front, $990M in milestones
Biogen announced an exclusive worldwide license to Vanqua Bio’s preclinical C5aR1 inhibitor, paying $70 million up front with up to $990 million in contingent payments. The deal hands Biogen...
Two nonhormonal menopause drugs win FDA nod — Bayer’s Lynkuet, elinzanetant
The FDA cleared Bayer’s Lynkuet for treatment of menopause-related hot flashes and separately approved elinzanetant as a nonhormonal option for vasomotor symptoms. Bayer said Lynkuet is the first...
Gepotidacin... approved for UTIs; gonorrhea filing remains active
Gepotidacin, a novel oral inhibitor of bacterial type II topoisomerases, received approval in March 2025 for uncomplicated urinary tract infections under the brand Blujepa and is under FDA review...
Halda posts first RIPTAC clinical data: prostate responses emerge
Halda Therapeutics released initial clinical readouts from an ongoing study of its RIPTAC platform in prostate cancer, reporting early signals of activity. The company described a first cut of...
Tetraneuron advances AAV gene therapy: targets E2F4 to restore memory
Spanish biotech Tetraneuron presented an upstream gene‑therapy approach—TET‑101—using AAV to modulate the transcription factor E2F4, aiming to halt neuronal cell‑cycle reentry and restore memory...
Nanopore pinpoints tissue‑of‑origin and pathogens in plasma cfDNA
Researchers deployed nanopore sequencing on plasma cell‑free DNA from critically ill patients to capture simultaneous tissue‑of‑origin signals and detect pathogenic DNA. The study demonstrated...
FDA flags unauthorized Indian API warehouse — lizards, cats found
The FDA issued an inspection report revealing an unauthorized warehouse in India holding active pharmaceutical ingredients and finished drugs that was reportedly infested with lizards and cats....
Metagenomic hunt uncovers retron editors — new gene‑editing candidates
Scientists screened bacterial and archaeal metagenomes to identify, test and begin improving retron‑based self‑priming gene editors compatible with Cas enzymes. The work yielded candidate retrons...